fbpx
星期一, 10 月 7, 2024

Consultation begins on new cancer medicines

Associate Health Minister for Pharmac David Seymour. Photo supplied

Associate Health Minister David Seymour says the recent announcement Pharmac is opening consultation on new cancer medicines is great news for Kiwi cancer patients and their families.

“As a result of the coalition Government’s $604 million funding boost, consultation is able to start for the first two targeted cancer treatments.

“More funding for cancer medicines means more choices and options available to Pharmac.

“On June 24, the Government announced it would deliver the funding boost so Pharmac could use its bargaining power to procure more medicines.

“I’m delighted that, less than two weeks later, the process is already underway.

“Pharmac should be praised for the speed with which it is moving.

“It is important to note Pharmac’s model is independent and designed to get the best value for New Zealanders in procuring these medicines, while the Government’s job is to make sure the right regulatory settings are in place and the funding is there for Pharmac.

“Ensuring that independence is very important to me.”

Seymour says consultation for the first tranche is open until Friday July 26.

Following that, a funding proposal will be taken to Pharmac’s board for a decision.

“For many New Zealanders, funding for pharmaceuticals is life or death, or the difference between a life of pain and suffering or living freely.

“New cancer medicines will make a significant difference to people’s lives by slowing the progression of their cancer.”

By clicking to accept for Times Online to be translated into Mandarin, you accept and acknowledge that it has been translated for your convenience using 3 rd party translation software. No automated translation is perfect, nor is it intended to replace human translators and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any translations made from English into Mandarin. Some content (such as images, videos etc.) may not be accurately translated due to the limitations of the translation software. The official text is the English version of the website. Any discrepancies or differences created in the translation are not binding and have no legal effect and should not be relied on by you for any decision-making purposes. If any questions arise related to the accuracy of the information contained in the translated website, refer to the English version of the website which is the official edited version.

点击同意将《时代在线》翻译成中文,即表示您接受并确认,该翻译是使用第三方软件为您方便起见而 提供的。请注意自动翻译并非完美无缺,也不旨在取代人工翻译,只能作为参考而已。对于英文到中文 的任何翻译的准确性、可靠性或正确性,我们不提供任何明示或暗示的保证。由于翻译软件的限制,某 些内容(如图片、视频等)可能无法准确翻译。   英文版本是本网站的官方正式文本。翻译中产生的任何差异或错误均不具有约束力,不具有法律效力, 您不应依赖由自动翻译软件生成的版本做出任何决策。如果对翻译后的网站中包含的信息的准确性有任 何疑问,请参阅本网站的官方编辑英文版本。

- 广告
- 广告

更多信息来自《泰晤士报在线

- 广告

最新

- 广告
- 广告